Patients and disease characteristics
| Characteristics . | Nonmyeloablative patients, n = 152 . | Myeloablative patients, n = 68 . |
|---|---|---|
| Median age, y (range) | 60 (18-70) | 46 (10-59) |
| Median follow-up, mo (range) | 44 (7-90) | 61 (21-97) |
| Median number of previous regimens (range) | 5 (1-13) | 3 (1-7) |
| Median interval between diagnosis and HCT, mo (range) | 7.0 (0.2-254) | 6.6 (0.2-157) |
| Previous autologous high-dose HCT, % | ||
| Overall | 52 | 10 |
| Planned/failed | 11/41 | 0/10 |
| Conditioning regimens, % | ||
| 2 Gy TBI | 18 | 0 |
| Flu + 2 Gy TBI | 82 | 0 |
| Cy + ≥12 Gy TBI | 0 | 87 |
| tBu + Cy | 0 | 13 |
| Diagnosis, % | ||
| NHL | 54 | 78 |
| Low-grade | 14 | 27 |
| High-grade | 40 | 51 |
| CLL | 26 | 15 |
| HD | 20 | 7 |
| Disease nature, %* | ||
| Indolent | 37 | 41 |
| Aggressive | 63 | 59 |
| Disease status at the time of HCT, % | ||
| Sensitive† | 46 | 25 |
| Refractory/untested relapse | 40/14 | 53/21 |
| Hematopoietic cell source, % | ||
| G-PBMC | 99 | 69 |
| Marrow | 1 | 31 |
| Donor type, % | ||
| HLA-matched sibling | 55 | 68 |
| HLA- antigen mismatched related | 1 | 4 |
| HLA-matched unrelated‡ | 39 | 25 |
| HLA- antigen mismatched unrelated | 5 | 3 |
| Patient CMV sero-status, % | ||
| Negative | 43 | 44 |
| Positive | 57 | 56 |
| Characteristics . | Nonmyeloablative patients, n = 152 . | Myeloablative patients, n = 68 . |
|---|---|---|
| Median age, y (range) | 60 (18-70) | 46 (10-59) |
| Median follow-up, mo (range) | 44 (7-90) | 61 (21-97) |
| Median number of previous regimens (range) | 5 (1-13) | 3 (1-7) |
| Median interval between diagnosis and HCT, mo (range) | 7.0 (0.2-254) | 6.6 (0.2-157) |
| Previous autologous high-dose HCT, % | ||
| Overall | 52 | 10 |
| Planned/failed | 11/41 | 0/10 |
| Conditioning regimens, % | ||
| 2 Gy TBI | 18 | 0 |
| Flu + 2 Gy TBI | 82 | 0 |
| Cy + ≥12 Gy TBI | 0 | 87 |
| tBu + Cy | 0 | 13 |
| Diagnosis, % | ||
| NHL | 54 | 78 |
| Low-grade | 14 | 27 |
| High-grade | 40 | 51 |
| CLL | 26 | 15 |
| HD | 20 | 7 |
| Disease nature, %* | ||
| Indolent | 37 | 41 |
| Aggressive | 63 | 59 |
| Disease status at the time of HCT, % | ||
| Sensitive† | 46 | 25 |
| Refractory/untested relapse | 40/14 | 53/21 |
| Hematopoietic cell source, % | ||
| G-PBMC | 99 | 69 |
| Marrow | 1 | 31 |
| Donor type, % | ||
| HLA-matched sibling | 55 | 68 |
| HLA- antigen mismatched related | 1 | 4 |
| HLA-matched unrelated‡ | 39 | 25 |
| HLA- antigen mismatched unrelated | 5 | 3 |
| Patient CMV sero-status, % | ||
| Negative | 43 | 44 |
| Positive | 57 | 56 |
Flu indicates fludarabine; and tBu, targeted busulfan.
Aggressive diseases included CLL with Richter's transformation, HD with the exception of nodular lymphocyte–predominant subtype, and aggressive lymphoma as defined by the Physician Data Query Modification of the Revised European American Lymphoma Classification of Lymphoproliferative Diseases (see http://www.cancer.gov/cancertopics/pdq/treatment/adult-non-hodgkins/HealthProfessional/page2#Section_17), whereas indolent diseases included all other histological subtypes.
Complete or partial remission.
Included 6 nonmyeloablative and 2 myeloablative patient/donor pairs with single allele mismatch.